Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock Jan 31, 2014 6:30 am EST
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure Jan 9, 2014 7:00 am EST
First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology Oct 15, 2013 8:00 am EDT
Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer Sep 17, 2013 1:18 pm EDT
Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study Jul 30, 2013 7:00 am EDT